Elevated expression of the anti-apoptotic factor survivin has been implicated in cancer cell survival and disease progression. However, its specific contribution to renal cell carcinoma (RCC) pathogenesis is not well defined. We investigated the roles of survivin in RCC tumor progression, resistance to mammalian target of rapamycin (mTOR) inhibitors, and evaluated the therapeutic activity of the survivin suppressant YM155 in RCC models. Here we report that survivin expression levels were significantly higher in RCC cell lines compared to normal 
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inhibition as a novel approach to improve RCC therapy that warrants further investigation.
Introduction
Survivin (BIRC5) is an inhibitor of apoptosis protein (IAP) family member with key roles in cell division and apoptosis suppression (1, 2) . Although it is highly expressed during embryonic and fetal development, survivin is not expressed in differentiated normal tissue except for the thymus, placenta, stem cell compartment, and basal epithelium of the colon (3) . A number of studies have demonstrated the frequent elevation of survivin levels across multiple tumor types and this aberrant expression is correlated with aggressive disease and shorter overall patient survival (4) (5) (6) (7) (8) . Due to its selected overexpression patterns and critical involvement in the control of cell proliferation and cell death, survivin is a promising target for therapeutic inhibition.
Targeted treatment options for renal cell carcinoma (RCC) include the mammalian target of rapamycin (mTOR) inhibitor temsirolimus and everolimus and the multi-targeted kinase inhibitors sorafenib and sunitinib. These agents have improved clinical outcomes, but drug resistance continues to be a major problem highlighting the need for novel therapeutic strategies (9, 10) . mTOR is a key regulator of protein synthesis that effects many cellular functions, including cell division, angiogenesis, and apoptosis. It is also an important downstream mediator of the phosphatidylinositol 3-kinase (PI3K)-AKT cell survival pathway that is deregulated in many cancers (11) in an increase in genes that promote angiogenesis (vascular endothelial growth factor (VEGF) and cell survival (survivin) (12) (13) (14) . Consistent with mTOR's role in these processes, we have previously shown that inhibition of mTOR decreases survivin levels, which significantly contributes to its anticancer activity (15) .
We hypothesized that targeting survivin may be an effective strategy for RCC therapy that will increase the benefit of mTOR inhibition. Here we report, that survivin is widely overexpressed in RCC cell lines and that its expression is required for RCC tumor progression as survivin silencing completely abrogated tumor growth. We further demonstrated that survivin expression directly regulated temsirolimus sensitivity using knockdown and overexpression approaches. The survivin suppressant YM155 exhibited promising activity in RCC models and augmented the in vitro and in vivo activity of temsirolimus through a mechanism characterized by cooperative depletion of survivin levels.
Collectively, our findings establish survivin as an essential regulator of both RCC progression and therapeutic sensitivity to temsirolimus. Clinical studies focused on targeting survivin expression as a new strategy to improve clinical outcomes for patients with RCC are warranted. First-strand cDNA synthesis was performed from 1 μg RNA in a 20 μl reaction mixture using the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY). BIRC5 transcripts were amplified using commercially available TaqMan® Gene expression assays (Applied Biosystems).
GAPDH was used as a housekeeping gene.
Quantification of drug-induced cytotoxicity
Cell viability was assessed by MTT assay. Cells were seeded into 96-well microculture plates at 10,000 cells per well and allowed to attach for 24 h. Cells were then treated with YM155, temsirolimus or the combination for 72 h. Survivin lentiviral shRNA and non-target control shRNA were obtained from Dharmacon (Lafayette, CO). Cells were infected with lentiviral particles in media with 5 μg/ml polybrene and incubated at 37°C for 24 h. Cells were cultured in 1 μg/ml puromycin to select for cells with stable knockdown of survivin expression.
Knockdown of survivin levels was determined by immunoblotting and quantified using ImageJ software. The following target sequences were used:
Survivin overexpression was carried out using the pORF5-hSurvivin expression vector (Invitrogen, San Diego, CA). Lyophilized GT100 E. coli bacteria transformed by pORF5-hSurvivin and pORF-mcs were streaked on an E. coli 
Statistical analyses
Statistical significance of differences observed between samples was determined using the Student's t test or the ANOVA -Tukey-Kramer Comparison Test where appropriate. Differences were considered significant in all experiments at p < 0.05.
Results

Potent knockdown of survivin is required to inhibit RCC tumor growth.
Survivin plays a key role in promoting cell cycle progression and inhibiting apoptosis (1) . In accordance with this, high survivin expression has been observed in many different cancer types and has been associated with tumor progression, drug resistance, and poor prognosis (17) (18) (19) (20) (21) . Therefore, targeting (Fig. 1C) . In agreement with the key role of survivin in tumor proliferation, cells with highly silenced survivin expression were unable to form tumors in mice (Fig. 1D) . Interestingly, moderate survivin knockdown did not alter tumor formation or tumor growth compared to cells transfected with control shRNA constructs. This suggests that even modest aberrant expression of survivin is sufficient to promote RCC pathogenesis.
Survivin expression regulates sensitivity to temsirolimus.
Although temsirolimus has demonstrated clinical benefit in RCC, drug resistance continues to be a major problem (22) . We hypothesized that survivin levels may control sensitivity to mTOR inhibitors. Temsirolimus treatment stimulated a dosedependent reduction in survivin expression in RCC cell lines ( Fig. 2A) . However, high dose temsirolimus was insufficient to completely reduce survivin expression. We further investigated the role of survivin as a regulator of temsirolimus sensitivity by assessing the impact of differential survivin expression on temsirolimus activity in paired 786-O cells with shRNA-mediated knockdown and forced overexpression. As expected, survivin knockdown significantly augmented temsirolimus-mediated apoptosis (Fig. 2B ) and overexpression promoted drug resistance (Fig. 2C) . These results suggest that targeting survivin levels may be an effective approach to enhance the anticancer activity of temsirolimus.
YM155 decreases survivin levels and induces apoptosis in RCC cells.
Considering that genetic inhibition of survivin yielded significant anti-RCC effects in our initial series of experiments, we next investigated the activity of the clinical survivin suppressant YM155 (Fig. 3A) . Treatment with YM155 selectively reduced survivin levels without significantly altering the expression levels of other IAPs, including cIAP-1, cIAP-2, and XIAP (Fig. 3B) . Consistent with the druginduced reduction in survivin levels, MTT assays demonstrated that YM155 treatment diminished RCC cell viability in a dose-dependent manner (Fig. 3C ).
YM155 also promoted apoptosis in RCC cells as measured by PI-FACS analysis (Fig. 3D ) and caspase-3 activation (Fig. 3E) Considering that our data demonstrated that survivin overexpression is sufficient confer resistance to temsirolimus, we next investigated the ability of YM155 to augment the anticancer activity of temsirolimus. Treatment with either YM155 or temsirolimus alone triggered a partial reduction in survivin expression (Fig. 4A) .
However, combination treatment resulted in a very substantial decrease in survivin levels (Fig. 4A ) that directly correlated with reduced RCC cell viability compared to single agent therapy (Fig. 4B) . Formal synergy analysis 
infusion, or the combination. Treatment with temsirolimus alone resulted in a dramatic decrease in mean tumor volume in 786-0 and Caki-1 tumors compared to the vehicle treated controls (Fig. 5A-B) . YM155 monotherapy also stimulated a reduction in tumor growth. Importantly, the combination significantly and more effectively decreased tumor burden in both 786-O and Caki-1 models compared to either single agent alone (Fig. 5A-B) . In addition, drug treatment with the combination was very well tolerated, as no significant animal weight loss was observed at the completion of the study (Fig. 5C ).
YM155 and temsirolimus decrease survivin expression, inhibit tumor cell proliferation, and stimulate apoptosis in vivo.
Two RCC xenograft studies demonstrated that YM155 augments the anticancer activity of temsirolimus in vivo. Since survivin is a key regulator of cell division and apoptosis and has been linked to drug resistance, we determined its expression in tumor specimens following drug treatment. Immunohistochemistry revealed that survivin levels were significantly reduced in tumors collected from temsirolimus and YM155 treated mice and the combination of both agents produced a further decrease in survivin expression (Fig. 6A) . The substantial reduction in survivin levels was linked to a significant decrease in tumor cell proliferation (Fig. 6B ) and corresponding increase in tumor cell apoptosis ( 
Discussion
The incidence and mortality of RCC has been increasing over the last several decades (23) . Current treatment options include mTOR inhibitors such as temsirolimus and the multi-targeted kinase inhibitors sorafenib and sunitinib (24) .
However, resistance to these agents is an emerging problem and new therapeutic strategies to circumvent and/or overcome drug resistance are clearly needed. Survivin is a key regulator of cell division, an inhibitor of apoptosis, and has also recently been identified as an important mediator of drug resistance (20, 25, 26) . Recent studies have suggested that survivin may play a key role in RCC pathogenesis as its high expression levels were linked to tumor aggressiveness and poor prognosis (6, 27, 28) . Loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene results in constitutive hypoxia inducible factor (HIF) expression and has been well documented in RCC (29) . However, a direct relationship between VHL status and response to VEGF or mTOR inhibitors has not been observed in clinical studies (30, 31) . Furthermore, the absence of RCC tumorigenesis in VHL-deficient mice along with genetic data collected from humans suggests that RCC development likely requires additional co-factors that may synergize with VHL loss to trigger oncogenic transformation (32) (33) (34) .
Interestingly, increased survivin levels were recently reported to be associated with hypoxia (35) . Therefore, it is possible that high HIF expression also contributes to survivin overexpression in RCC. Consistent with these findings, we Our findings are in agreement with previous reports demonstrating that survivindeficient cells have low tumor formation in xenografts (36, 37) . Interestingly, a partial decrease (60% knockdown) in survivin levels did not alter tumor growth compared to control shRNA-transfected cells suggesting that a high threshold of survivin depletion must be reached in order to achieve therapeutic benefit.
While a plethora of studies confirm the importance of survivin as a catalyst of cancer progression, few agents that selectively target its expression currently exist. Several approaches to disrupt its function have been used including the use of antisense oligonucleotides such as SPC3042 and small molecule inhibitors such as YM155 and terameprocol (EM1421) (38, 39) . YM155 was identified in a high-throughput screen to identify agents that selectively block survivin promoter activity and is the most clinically advanced of this new class of agents (40) . It has demonstrated activity against various tumor types in preclinical studies (19, (40) (41) (42) (43) . We selected the VHL null 786-O and the VHL wild-type Caki-1 cell lines as models for our xenograft studies as they both Several clinical studies of YM155 revealed that it was very well-tolerated, but likely would be best utilized in combination chemotherapy due to its limited single agent efficacy (44) (45) (46) (47) (48) . Multiple combination studies with YM155 were conducted with paclitaxel or docetaxel regimens based on the rationale that YM155 may be able to overcome taxane-mediated upregulation of survivin expression, which promotes drug resistance (44, (48) (49) (50) . However, the lack of efficacy that was observed in these clinical studies may have been due to incomplete suppression of survivin levels in the tumors. As demonstrated by our survivin silencing studies, a very high degree of survivin depletion is required to achieve antitumor efficacy. We hypothesized that combining YM155 with another agent that reduces survivin expression may yield a more potent decrease in survivin expression and improve efficacy. Inhibitors of PI3K, AKT, mTOR, histone deacetylase (HDAC) and MEK/ERK signaling have all been reported to modulate survivin expression (15, 17) . We focused on the mTOR inhibitor temsirolimus rather than the VEGF/multi-tyrosine kinase inhibitors (sunitinib and sorafenib) MCT-14-1036 due to its ability to significantly decrease survivin expression in our preclinical models and its considerable activity against RCC. Consistent with our hypothesis, the addition of YM155 to temsirolimus synergistically reduced survivin expression in RCC cell lines and significantly decreased tumor burden in both tested RCC xenograft models compared to single agent treatment. Analysis of tumor specimens taken following treatment revealed highly depleted survivin levels and increased induction of apoptosis indicating that tumor cell death directly contributed to the activity of this combination. In our study, temsirolimus exhibited limited in vitro pro-apoptotic activity, but displayed potent anticancer activity in vivo. This observation may be, in part, due to the ability of mTOR inhibitors to block angiogenesis, which results in a more robust antitumor response in xenograft studies. Importantly, we demonstrated that the limited cytotoxicity of temsirolimus could be enhanced through depletion of survivin levels.
Our collective findings demonstrate that survivin expression is essential for RCC progression and is a key mediator of resistance to temsirolimus. Our 
